Friday, July 10, 2026

Drug profile · INN

eliglustat

eliglustat (CERDELGA) is a ceramide glucosyltransferase inhibitor.

EMA: approved Alimentary tract and metabolism (A16) A16AX10
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — eliglustat
Class
Alimentary tract and metabolism (A16)
Route
Patents
0
Programs
1
Data quality
0.83

Quick answer

eliglustat (CERDELGA) is a ceramide glucosyltransferase inhibitor.

Key facts

INN eliglustat
Brand CERDELGA
Mechanism Ceramide glucosyltransferase inhibitor
Therapeutic class Alimentary tract and metabolism (A16)
ATC code A16AX10

Mechanism of action

Ceramide glucosyltransferase inhibitor

Approval history

Authority Status Date
EMA approved

Pipeline programs

  1. EFC13738 Phase 3 · Genzyme Europe · Gaucher's disease type I; Gaucher's disease type III

Related & competitor drugs

  1. agalsidase alfa Alimentary tract and metabolism (A16)
  2. alogliptin Alimentary tract and metabolism (A10)
  3. alogliptin benzoate Alimentary tract and metabolism (A10)
  4. aprepitant Alimentary tract and metabolism (A04)
  5. budesonide Alimentary tract and metabolism (A07)
  6. canagliflozin Alimentary tract and metabolism (A10)

Frequently asked questions

What is eliglustat?

eliglustat (CERDELGA) is a ceramide glucosyltransferase inhibitor.

What is the brand name for eliglustat?

CERDELGA is a marketed brand name for eliglustat. Check FDA Drugs@FDA for the current US label holder and prescribing information.